Little House Capital’s GSK GSK Stock Holding History

Little House Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$10K	–	167
2019 Q1	$10K	Buy	+200	New	+$9.99K	0.01%	246

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Little House Capital's GSK Position: Q2 2019 in Review

Little House Capital sold out of GSK (GSK) in Q2 2019, closing a stake of 200 shares — an estimated $10K sold.

Little House Capital first reported a position in GSK in Q1 2019 and held it in 1 quarter. The position peaked at $10K in Q1 2019. 804 funds tracked by Wall St. Rank hold GSK as of Q2 2019.

Little House Capital reported no remaining GSK position as of Q2 2019 after selling out during the quarter.
Little House Capital sold 200 GSK shares in Q2 2019, an estimated $10K.
Little House Capital first reported a position in GSK in Q1 2019 and held it in 1 quarter.
Little House Capital's GSK position peaked at $10K in Q1 2019.
804 funds tracked by Wall St. Rank held GSK as of Q2 2019.

Based on Little House Capital's 13F filing for Q2 2019, filed 14 Aug 2019.